• Subjects must have histologically confirmed non-Hodgkin lymphoma relapsed after 2 or more lines of therapy or disease refractory to chemotherapy (defined as progressive disease or stable disease lasting ≤6 months, as best response to most recent chemotherapy regimen; or disease progression or recurrence ≤12 months after prior autologous stem cell transplantation (ASCT).

• No evidence of central nervous system (CNS) lymphoma.

• Male or female \> 18 years of age.

• Eastern Cooperative Oncology Group Performance status ≤ 2.

• At least one measurable lesion.

• \>2 weeks since prior radiation therapy or systemic therapy at the time of leukapheresis.

• Total bilirubin ≤ 1.5 mg/dL (except in patients with Gilbert's syndrome).

• Aspartate aminotransferase/alanine transferase ≤ 2.5 X institutional upper limit of normal.

• Serum creatinine \< 1.5 mg/dL.

⁃ Cardiac ejection fraction of \>50%, and no evidence of pericardial effusion, as determined by an echocardiogram.

⁃ Adequate pulmonary function as defined as pulse oximetry ≥ 92% on room air.

⁃ Subjects (or legal guardians) must have the ability to understand and the willingness to sign a written informed consent document.

⁃ For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of \< 1% per year during the treatment period and for at least 90 days after the BAFF CAR-T cell infusion.

⁃ For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.